264 related articles for article (PubMed ID: 20381283)
1. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
Epstein RS; Moyer TP; Aubert RE; O Kane DJ; Xia F; Verbrugge RR; Gage BF; Teagarden JR
J Am Coll Cardiol; 2010 Jun; 55(25):2804-12. PubMed ID: 20381283
[TBL] [Abstract][Full Text] [Related]
2. The long and winding road to warfarin pharmacogenetic testing.
Ginsburg GS; Voora D
J Am Coll Cardiol; 2010 Jun; 55(25):2813-5. PubMed ID: 20579536
[No Abstract] [Full Text] [Related]
3. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
4. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice.
van der Zee SA; Halperin JL
Nat Rev Cardiol; 2010 Oct; 7(10):549-50. PubMed ID: 20865027
[No Abstract] [Full Text] [Related]
6. Refining the use of warfarin through genetic testing.
Lee SC
Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
Patrick AR; Avorn J; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
[TBL] [Abstract][Full Text] [Related]
8. Pathology consultation on warfarin pharmacogenetic testing.
Stack G;
Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Eckman MH; Rosand J; Greenberg SM; Gage BF
Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of warfarin: current status and future challenges.
Wadelius M; Pirmohamed M
Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
[TBL] [Abstract][Full Text] [Related]
11. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic testing for warfarin dosing: we are ready now.
Wu AH
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
[No Abstract] [Full Text] [Related]
13. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.
McClain MR; Palomaki GE; Piper M; Haddow JE
Genet Med; 2008 Feb; 10(2):89-98. PubMed ID: 18281915
[TBL] [Abstract][Full Text] [Related]
14. [Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study].
Sychev DA; Antonov IM; Ignat'ev IV; Naumova IuV; Dmitriev VA; Kropacheva ES; Dobrovol'skiĭ OB; Panchenko EP; Tashenova IA; Kukes VG
Kardiologiia; 2010; 50(5):42-6. PubMed ID: 20831047
[TBL] [Abstract][Full Text] [Related]
15. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
16. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
You JH; Tsui KK; Wong RS; Cheng G
Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
[TBL] [Abstract][Full Text] [Related]
17. Will there be a role for genotyping in warfarin therapy?
Gandara E; Wells PS
Curr Opin Hematol; 2010 Sep; 17(5):439-43. PubMed ID: 20601874
[TBL] [Abstract][Full Text] [Related]
18. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
[TBL] [Abstract][Full Text] [Related]
19. Warfarin and pharmacogenomic testing: what would Pascal do?
Teagarden JR
Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
[No Abstract] [Full Text] [Related]
20. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A
J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
